ABSTRACT
Liposomes are biodegradable and biocompatible and are sufficiently nontoxic and nonimmunogenic for systemic and nonsystemic administrations. Evaluation of the ability of liposomes to act as sustained-release depots is essentially a diffusion study that requires the ability to separate this process from drug release that is due to liposomal damage. Target definition was deemed essential beginning any discussion on the deficiencies of regular liposomes relative to drug targeting in topical wound and burn therapies and of potential means to remedy the situation. Drug release from intact liposomes into the medium within which the liposomes are placed, is essentially a process of diffusion in a heterogeneous system, the studies of which can be started at the test tube level. To provide a significant improvement in the clinical outcome, antibiotic, growth factor delivery system would have to successfully tackle the problems that arise from the exposure of the free drug to the wound, at the same time, address the issues of treatment regimens.
